Clinical Trial Update: Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating intratumoral ISF35 (rAd.CD40L) in combination with pembrolizumab for refractory metastatic melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ISF35 (rAd.CD40L)
• Keytruda (Pembrolizumab) (pembrolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Melanoma | Phase 1, Phase 2 | Status: WITHDRAWN